Abstract: Provided herein are pharmaceutical compositions comprising therapeutic agent(s) and functional excipients that can enable oral absorption of small molecules and/or large molecules. Also provided herein are methods of preparing the pharmaceutical composition and methods of using the same for treating various diseases or disorders such as type-2 diabetes, obesity, NASH, renal disease.

Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.

Abstract: Provided herein are pharmaceutical compositions comprising a heparin and functional excipients that can enhance oral bioavailability of the heparin. Also provided herein are methods of preparing the pharmaceutical composition and methods of using the same for treating various diseases or disorders such as DVT.

Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.

Abstract: Provided herein are ketamine gel formulations, transdermal delivery devices comprising ketamine, methods of preparation and methods of using thereof. The transdermal delivery device can be a drug-in-reservoir (DIR) patch comprising ketamine, which typically includes a backing layer, a reservoir layer comprising a ketamine gel formulation, a rate-controlling membrane, an adhesive layer, and a release liner. The ketamine gel formulation generally includes one or more skin permeation enhancers. The transdermal delivery devices can be configured, for example, by adjusting the ketamine gel formulation and other release control mechanism, to provide certain skin flux characteristics, and can be used for treating a variety of indications such as depression and/or pain.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.

Abstract: Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.

Abstract: Provided herein are film compositions comprising ketamine suitable for delivering ketamine across oral mucosal membranes. The film compositions can have various designs such as quick-release film, slow-release film, bilayer film that combines both a quick-release and slow-release film, or one-directional release film. Further are included methods of using the film compositions herein for the treatment of various diseases or disorders, such as pain and/or depression.

Abstract: Provided herein are ketamine gel formulations, transdermal delivery devices comprising ketamine, methods of preparation and methods of using thereof. The transdermal delivery device can be a drug-in-reservoir (DIR) patch comprising ketamine, which typically includes a backing layer, a reservoir layer comprising a ketamine gel formulation, a rate-controlling membrane, an adhesive layer, and a release liner. The ketamine gel formulation generally includes one or more skin permeation enhancers. The transdermal delivery devices can be configured, for example, by adjusting the ketamine gel formulation and other release control mechanisms, to provide certain skin flux characteristics, and can be used for treating a variety of indications such as depression and/or pain.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.

Abstract: The invention provides the uses of fibrinogen-420 or alpha EC domain thereof, for inhibiting protein aggregation, refolding the denatured proteins, manufacturing drugs for prevention and/or treatment of protein misfolding diseases, resisting protein denaturation, and detecting the quality of protein products. The invention also provides the drugs for prevention and/or treatment of protein misfolding diseases or protein denatured disease, and the protein stabilizer. The active ingredient of the said drugs and stabilizer is fibrinogen-420 or alpha EC domain thereof.

Abstract: Polymerizable ionic liquid monomers and their corresponding polymers (poly(ionic liquid)s) are created and found to exhibit high absorption of radio frequency electromagnetic radiation, particularly in the microwave and radar bands. These materials are useful for coating objects to make them less reflective of radio frequency radiation and for making objects that absorb radio frequency radiation and are of minimal reflectivity to radio frequency radiation. Free-radical and condensation polymerization approaches are used in the preparation of the poly(ionic liquids).

Abstract: The invention discloses a novel application of fibrinogen-420 and its active domain (alpha EC domain), and a separate alpha EC domain protein has the same or similar function with fibrinogen-420. Fibrinogen-420 and its active domain can be widely used in inhibiting protein aggregation, helping protein refolding, drugs which can prevent and/or treat protein conformation disease, detecting denatured protein in quality control and protect protein from denaturation.

Abstract: The invention discloses a novel application of fibrinogen-420 and its active domain (alpha EC domain), and a separate alpha EC domain protein has the same or similar function with fibrinogen-420. Fibrinogen-420 and its active domain can be widely used in inhibiting protein aggregation, helping protein refolding, drugs which can prevent and/or treat protein conformation disease, detecting denatured protein in quality control and protect protein from denaturation.

Abstract: Curcumin, a polyphenol extracted from the rhizome turmeric, has been polymerized to produce a polymer material having a backbone of one or more repeating structural units, at least one of which comprises a curcumin monomer residue. These curcumin-containing polymers have a wide range of pharmacological activities, including, among others antitumor, antioxidant, antiinflammatory, antithrombotic and antibacterial activities. Certain species of these polymers have exhibited remarkable antitumor activity. Water-soluble curcumin derivatives and their use as prodrugs and prodrug carriers are also disclosed.

Abstract: A class of catalysts with unusually high activity for polymerizing vinyl monomers such as acrylates, methacrylates and styrene is described. The catalysts consists of a metal halide such as CuBr and FeBr2 ligated with multidentate amine-based ligands, for example N,N,N?,N?-tetra[(2-pyridal)methyl]ethylenediamine, and additives. The additives, which are tertiary amine compounds, can greatly increase the catalytic activity. The complex is capable of catalyzing a living polymerization reaction at a concentration of the complex below about 0.1 mol %.

Abstract: Disclosed are new, highly active and versatile atom transfer radical polymerization (ATRP) catalysts. These catalysts catalyze ATRP for acrylates, methacrylates, and styrenes at surprisingly low concentrations. These catalysts mediated ATRP at a catalyst/initiator molar ratio at 0.005 and produced polymers with well-controlled molecular weights and low polydispersities. ATRP occurred even at a catalyst/initiator molar ratio as low as 0.001 with metal concentration in the produced polymers as low as 6-8 ppm. Amine-containing compounds, such as triethylamine, can significantly increase the catalyst activity of theses catalysts. The amine compounds can also used to the terminal halogen groups such as Br and Cl in the polymers prepared by ATRP.

Abstract: Polymerizable ionic liquid monomers and their corresponding polymers (poly(ionic liquid)s) are created and found to exhibit high absorption of radio frequency electromagnetic radiation, particularly in the microwave and radar bands. These materials are useful for coating objects to make them less reflective of radio frequency radiation and for making objects that absorb radio frequency radiation and are of minimal reflectivity to radio frequency radiation. Free-radical and condensation polymerization approaches are used in the preparation of the poly(ionic liquids).

Abstract: A class of catalysts with unusually high activity for polymerizing vinyl monomers such as acrylates, methacrylates and styrene is described. The catalysts consists of a metal halide such as CuBr and FeBr2 ligated with multidentate amine-based ligands, for example N,N,N?,N?-tetra[(2-pyridal)methyl]ethylenediamine, and additives. The additives, which are tertiary amine compounds, can greatly increase the catalytic activity. The complex is capable of catalyzing a living polymerization reaction at a concentration of the complex below about 0.1 mol %.